✦ LIBER ✦

A Phase II Study of Weekly Paclitaxel/Estramustine/Carboplatin in Hormone-Refractory Prostate Cancer

✍ Scribed by William Berry; David Friedland; John Fleagle; Don Jackson; Des Ilegbodu; Kristi A. Boehm; Lina Asmar

Book ID: 119935392
Publisher: CIG Media Group, LP.
Year: 2006
Tongue: English
Weight: 149 KB
Volume: 5
Category: Article
ISSN: 1558-7673
DOI: 10.3816/cgc.2006.n.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination chemotherapy with weekly pac

Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer

✍ Tomihiko Yasufuku; Katsumi Shigemura; Osamu Matsumoto; Soichi Arakawa; Masato Fu 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 168 KB

Phase-II Study of Docetaxel, Estramustin

Phase-II Study of Docetaxel, Estramustine Phosphate, and Carboplatin in Patients with Hormone-Refractory Prostate Cancer

✍ Nobuyuki Kikuno; Shinji Urakami; Shigeru Nakamura; Takeo Hiraoka; Taijyu Hyuga; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 176 KB

Phase II Randomized Trial of Weekly Pacl

Phase II Randomized Trial of Weekly Paclitaxel with or Without Estramustine Phosphate in Progressive, Metastatic, Hormone-Refractory Prostate Cancer

✍ Berry, William R.; Hathorn, James W.; Dakhil, Shaker R.; Loesch, David M.; Jacks 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 140 KB

Phase I trial of weekly paclitaxel plus

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer

✍ Naomi Haas; Bruce Roth; Carlos Garay; Gwen Yeslow; Michael Entmacher; Alan Weins 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 174 KB

Monthly paclitaxel and carboplatin with

Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer

✍ Takehiko Segawa; Toshiyuki Kamoto; Hidefumi Kinoshita; Yasuharu Kunishima; Koji 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 378 KB

Phase II trial of paclitaxel, estramusti

Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma

✍ David C. Smith; Christopher H. Chay; Rodney L. Dunn; Jude Fardig; Peg Esper; Kar 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract ## BACKGROUND Preclinical data suggest that the combination of intravenous (i.v.) paclitaxel, carboplatin, oral etoposide, and oral estramustine (TEEC) has significant activity in patients with advanced, hormone‐refractory prostate carcinoma. The authors conducted this clinical trial t